Table 1 Demographics and clinical characteristics of HCC patients before and after one-to-one propensity score matching analysis
Variables | All patients | Propensity-matched patients | ||||
|---|---|---|---|---|---|---|
HR (n = 280) | TACE (n = 899) | P value | HR (n = 244) | TACE (n = 244) | P value | |
Year of treatment (−09/10-) [n (%)] | 169(60)/111(40) | 359(40)/540(60) | < 0.001 | 137(56)/107(44) | 141(58)/103(42) | 0.715 |
Age (y) | 48.77 ± 12.90 | 51.04 ± 11.47 | 0.009 | 49.5 ± 13.0 | 48.9 ± 11.9 | 0.584 |
Gender (male/female) [n (%)] | 254(91)/26(9) | 826(92)/73(8) | 0.539 | 222(91)/22 (9) | 215(88)/29 (12) | 0.300 |
Etiology (HBV related/none) [n (%)] | 245 (88)/35(12) | 810 (90)/89 (10) | 0.216 | 212 (87)/ 32(13) | 209 (86)/35(14) | 0.693 |
PLT (109/L) | 204.9 ± 81.9 | 199.8 ± 88.8 | 0.395 | 200.9 ± 80.0 | 197.4 ± 79.0 | 0.622 |
PT (sec) | 12.3 ± 1.2 | 12.7 ± 1.4 | < 0.001 | 12.3 ± 1.2 | 12.3 ± 1.3 | 0.955 |
AST (U/L) | 55.4 ± 39.5 | 80.7 ± 65.3 | < 0.001 | 56.7 ± 41.2 | 60.3 ± 30.9 | 0.271 |
ALB (g/L) | 41.1 ± 4.0 | 40.0 ± 4.2 | < 0.001 | 41.0 ± 3.8 | 41.1 ± 4.0 | 0.769 |
TBIL (μmol/L) | 19.8 ± 40.4 | 18.2 ± 12.1 | 0.525 | 16.1 ± 18.3 | 17.8 ± 17.9 | 0.298 |
C-P grade (A/B) [n (%)] | 273(98)/7(2) | 851(95)/48(5) | 0.049 | 240(98)/4 (2) | 238(98)/6 (2) | 0.523 |
ALBI (level 1/level 2–3) [n (%)] | 193(69)/87(31) | 469(52)/430(48) | < 0.001 | 165(68)/79 (32) | 161(66)/83(34) | 0.701 |
AFP (≤ 400 μg/L / > 400 μg/L) [n (%)] | 127(45)/153(55) | 402(45)/497(55) | 0.851 | 113(46)/131(54) | 115(47)/129 (53) | 0.856 |
Tumor size (cm) | 8.5 ± 3.2 | 9.5 ± 3.2 | < 0.001 | 9.0 ± 3.1 | 8.6 ± 3.2 | 0.147 |
Tumor numbers (1/2-) [n (%)] | 119(43)/161(57) | 175(19)/724(81) | < 0.001 | 88/156 (36/64) | 85/159 (35/65) | 0.776 |
UICC stage (IIIa / IIIb) [n (%)] | 136(49)/144(51) | 502(56)/397(44) | 0.033 | 129(53)/115(47) | 134(55)/110(45) | 0.650 |